Biotechnology Company Announces Major Agreement For Worldwide Exclusive Rights
Kineta Announces Exclusivity and Right of First Offer Agreement for VISTA Blocking Antibody with TuHURA Biosciences.
Disclaimer: The information provided in this article is based on the announcement made by Kineta, Inc. and is intended solely for informational purposes. It should not be construed as investment advice or an endorsement of any company or product.
Real-time information is available daily at https://stockregion.net
Kineta, Inc. (Nasdaq: KA), a clinical-stage biotechnology company dedicated to the development of novel immunotherapies aimed at overcoming cancer immune resistance, has recently announced a massive milestone. The company has entered into an exclusivity and right of first offer agreement (the "Agreement") with TuHURA Biosciences, Inc. ("TuHURA"), a Phase 3 registration-stage immune-oncology company known for its innovative technologies designed to combat resistance to cancer immunotherapy.
Details of the Agreement
Under the terms of the Agreement, Kineta has granted TuHURA an exclusive right to acquire its worldwide patents, patent rights, patent applications, product and development program assets, technical and business information, and other associated rights and assets linked to its development program related to KVA12123. This exclusive right will remain effective until the earlier of either the execution of any definitive agreement concerning a potential transaction by TuHURA or one or more of its affiliates, or 11:59 PM Eastern Time on October 1, 2024, with the possibility of extension.
As part of the Agreement, TuHURA will provide Kineta with a nonrefundable payment of $5 million, ensuring Kineta's compliance with its obligations set forth in the Agreement. This financial consideration presents the of the collaboration and the potential value of Kineta’s VISTA blocking antibody program. KVA12123 is a cutting-edge VISTA (V-domain Ig suppressor of T cell activation) blocking monoclonal antibody currently being evaluated in a Phase 1/Phase 2 clinical trial for patients with advanced solid tumors. The trial consists of two arms: a monotherapy arm with KVA12123 alone and a combination arm that pairs KVA12123 with Merck’s anti-PD1 therapy, KEYTRUDA (pembrolizumab).
Initial results from the study were reported in April 2023 at the American Association of Cancer Research. To date, the drug has demonstrated a favorable safety profile, with no dose-limiting toxicities or cytokine release syndrome observed. Additional data from the study are anticipated to be released in the fourth quarter of 2024.
Partnership with TuHURA Biosciences
Craig W. Philips, President of Kineta, expressed confidence in TuHURA Biosciences’ capacity to advance the KVA12123 program. He stated, "TuHURA Biosciences is well-positioned to advance KVA12123. TuHURA is a Phase 3 registration stage immuno-oncology company with expertise and deep experience in the field. We believe they will make an excellent partner for this program and in advancing this novel drug program which could provide an important new treatment option for cancer patients."
The partnership between Kineta and TuHURA Biosciences brings together two companies with a shared commitment to developing breakthrough therapies that address the unmet needs of cancer patients. TuHURA’s expertise in immune-oncology and its established track record in advancing novel therapies through late-stage clinical trials make it a fitting collaborator to drive forward the development of KVA12123. Kineta (Nasdaq: KA) is a clinical-stage biotechnology company with a mission to develop next-generation immunotherapies that transform patients’ lives. Leveraging its expertise in innate immunity, Kineta is focused on discovering and developing potentially differentiated immunotherapies that address the major challenges associated with current cancer therapies.
The company’s immuno-oncology pipeline includes KVA12123, a novel VISTA blocking immunotherapy currently in a Phase 1/2 clinical trial involving patients with advanced solid tumors, and a preclinical monoclonal antibody targeting CD27. Kineta’s approach aims to offer new hope to patients who have limited treatment options, potentially shifting the paradigm in cancer care. The exclusivity and right of first offer agreement between Kineta and TuHURA Biosciences marks a pivotal step in the development and potential commercialization of KVA12123. With TuHURA’s expertise and resources, there is a promising path forward for this innovative immunotherapy, which could ultimately benefit patients with advanced solid tumors who are in need of new treatment options.
Disclaimer: The information in this article is provided for general informational purposes only and should not be construed as investment advice or an endorsement of any company or product.
Real-time information is available daily at https://stockregion.net